GRANULES Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for GRANULES from our risk checks.
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹529.10 |
| 52 Week High | ₹721.00 |
| 52 Week Low | ₹360.10 |
| Beta | 0.21 |
| 11 Month Change | -11.41% |
| 3 Month Change | -21.67% |
| 1 Year Change | 44.11% |
| 33 Year Change | 74.48% |
| 5 Year Change | 302.97% |
| Change since IPO | 4,980.17% |
Recent News & Updates
Recent updates
Is Granules India (NSE:GRANULES) Using Too Much Debt?
Sep 16
Granules India Limited (NSE:GRANULES) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 02Granules India Limited (NSE:GRANULES) Stock Rockets 27% But Many Are Still Ignoring The Company
Aug 01Granules India Limited's (NSE:GRANULES) CEO Compensation Is Looking A Bit Stretched At The Moment
Jul 31Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50
Jul 17Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50
Jun 19Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Many Still Looking Away From Granules India Limited (NSE:GRANULES)
Dec 28Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Nov 13A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)
Oct 24Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
May 19Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?
Mar 29Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Jan 19Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
Oct 01Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Aug 18Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75
Jul 14Is Granules India (NSE:GRANULES) A Risky Investment?
Jun 28Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75
Jun 09Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)
May 06Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25
Feb 10Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Feb 02Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Dec 21Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock
Aug 18Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25
Aug 03Is Granules India (NSE:GRANULES) Using Too Much Debt?
Jun 11Shareholder Returns
| GRANULES | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.5% | -3.1% | -3.4% |
| 1Y | 44.1% | 41.1% | 27.0% |
Return vs Industry: GRANULES exceeded the Indian Pharmaceuticals industry which returned 42.9% over the past year.
Return vs Market: GRANULES exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| GRANULES volatility | |
|---|---|
| GRANULES Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: GRANULES has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GRANULES's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 4,057 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology.
Granules India Limited Fundamentals Summary
| GRANULES fundamental statistics | |
|---|---|
| Market cap | ₹128.26b |
| Earnings (TTM) | ₹4.87b |
| Revenue (TTM) | ₹44.78b |
26.3x
P/E Ratio2.9x
P/S RatioIs GRANULES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRANULES income statement (TTM) | |
|---|---|
| Revenue | ₹44.78b |
| Cost of Revenue | ₹19.28b |
| Gross Profit | ₹25.50b |
| Other Expenses | ₹20.63b |
| Earnings | ₹4.87b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.10 |
| Gross Margin | 56.94% |
| Net Profit Margin | 10.88% |
| Debt/Equity Ratio | 29.5% |
How did GRANULES perform over the long term?
See historical performance and comparison